| 摘要 |
<p num="1"><br/><br/><br/>Pharmaceutical formulations in an aqueous (preferably, sprayable) formulaiton <br/>including an immune response modifier (IRM), such as those chosen from <br/>imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine <br/>amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged <br/>imidazoquinoline amines, imidazonaphthyridine amines, <br/>imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, <br/>thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, <br/>oxazolonaphthyridine amines, thiazolonaphthyridine amines, and 1H-imidazo <br/>dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, <br/>naphthyridine amines, or tetrahydronaphthyridine amines, are provided. In one <br/>embodiment, the aqueous formulations are advantageous for treatment and/or <br/>prevention of allergic rhinitis, viral infections, sinusitis, and asthma.<br/>
|
